NASDAQ:LNTH Lantheus (LNTH) Stock Price, News & Analysis → Top Project Outperforms BTC in 2023… (From Crypto 101 Media) (Ad) Free LNTH Stock Alerts $60.46 +1.71 (+2.91%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$59.38▼$60.5150-Day Range$51.07▼$68.2652-Week Range$50.20▼$100.85Volume687,850 shsAverage Volume903,187 shsMarket Capitalization$4.14 billionP/E Ratio13.03Dividend YieldN/APrice Target$104.14 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Lantheus alerts: Email Address Lantheus MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside72.3% Upside$104.14 Price TargetShort InterestBearish7.74% of Float Sold ShortDividend StrengthN/ASustainability-1.67Upright™ Environmental ScoreNews Sentiment1.07Based on 5 Articles This WeekInsider TradingAcquiring Shares$57.41 M Bought Last QuarterProj. Earnings Growth-3.67%From $5.72 to $5.51 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.63 out of 5 starsMedical Sector86th out of 939 stocksDiagnostic Substances Industry2nd out of 13 stocks 3.4 Analyst's Opinion Consensus RatingLantheus has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $104.14, Lantheus has a forecasted upside of 72.3% from its current price of $60.46.Amount of Analyst CoverageLantheus has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.74% of the float of Lantheus has been sold short.Short Interest Ratio / Days to CoverLantheus has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Lantheus has recently decreased by 0.77%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldLantheus does not currently pay a dividend.Dividend GrowthLantheus does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreLantheus has received a 61.07% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for cancer", "Diagnostic radiopharmaceuticals", and "Therapeutic radiopharmaceuticals" products. See details.Environmental SustainabilityThe Environmental Impact score for Lantheus is -1.67. Previous Next 3.4 News and Social Media Coverage News SentimentLantheus has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Lantheus this week, compared to 6 articles on an average week.Search Interest33 people have searched for LNTH on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.MarketBeat Follows16 people have added Lantheus to their MarketBeat watchlist in the last 30 days. This is an increase of 60% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lantheus insiders have bought 830.74% more of their company's stock than they have sold. Specifically, they have bought $57,409,487.00 in company stock and sold $6,168,153.00 in company stock.Percentage Held by InsidersOnly 1.50% of the stock of Lantheus is held by insiders.Percentage Held by Institutions99.06% of the stock of Lantheus is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Lantheus are expected to decrease by -3.67% in the coming year, from $5.72 to $5.51 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lantheus is 13.03, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 138.66.Price to Earnings Ratio vs. SectorThe P/E ratio of Lantheus is 13.03, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 199.58.Price to Book Value per Share RatioLantheus has a P/B Ratio of 5.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaTop Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.Just click here for instant access to the #1 Coin for 2024. About Lantheus Stock (NASDAQ:LNTH)Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Read More LNTH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LNTH Stock News HeadlinesMarch 11, 2024 | insidertrades.comInsider Buying: Lantheus Holdings, Inc. (NASDAQ:LNTH) Major Shareholder Purchases 60,431,039 Shares of StockMarch 24, 2024 | finance.yahoo.comInvesting in Lantheus Holdings (NASDAQ:LNTH) three years ago would have delivered you a 198% gainMarch 28, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.March 20, 2024 | finance.yahoo.comLNTH Oct 2024 70.000 callMarch 20, 2024 | americanbankingnews.comLantheus Holdings, Inc. (NASDAQ:LNTH) Receives Consensus Rating of "Moderate Buy" from BrokeragesMarch 19, 2024 | ca.finance.yahoo.comLNTH Oct 2024 80.000 callMarch 19, 2024 | ca.finance.yahoo.comLNTH Oct 2024 50.000 putMarch 11, 2024 | finance.yahoo.comInsider Sell: President Paul Blanchfield Sells Shares of Lantheus Holdings Inc (LNTH)March 28, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.March 8, 2024 | finance.yahoo.comLantheus Holdings (LNTH) Stock Moves -0.11%: What You Should KnowMarch 8, 2024 | finance.yahoo.comDirector Sam Leno Sells Shares of Lantheus Holdings Inc (LNTH)March 7, 2024 | markets.businessinsider.comBuy Rating on Lantheus Holdings Amid Overlooked Pylarify Growth and Market Expansion OpportunitiesMarch 6, 2024 | investing.comFDA approves Lantheus' DEFINITY for pediatric echocardiogramsMarch 5, 2024 | finance.yahoo.comPerspective Therapeutics Acquires CGMP-Compliant Manufacturing FacilityMarch 5, 2024 | globenewswire.comLantheus to Present at the Leerink Partners Global Biopharma Conference 2024March 4, 2024 | finance.yahoo.comLantheus Announces the FDA Approval of DEFINITY® (Perflutren Lipid Microsphere) for Pediatric PatientsMarch 3, 2024 | realmoney.thestreet.comThis Mid-Cap Healthcare Stock Is Lining Up for Another Successful TradeFebruary 28, 2024 | globenewswire.comLantheus Announces Promotion of Amanda Morgan to Chief Commercial OfficerFebruary 27, 2024 | seekingalpha.comLantheus Holdings: Undervalued With A Good OutlookFebruary 26, 2024 | globenewswire.comLantheus to Present at the TD Cowen 44th Annual Health Care ConferenceFebruary 26, 2024 | markets.businessinsider.comLantheus Holdings: A Strong Buy on Robust Pylarify Performance and Favorable Market DynamicsFebruary 26, 2024 | markets.businessinsider.comLantheus Holdings: Strong Buy on Robust Q4 Earnings and Promising Growth ProspectsFebruary 24, 2024 | finance.yahoo.comIf EPS Growth Is Important To You, Lantheus Holdings (NASDAQ:LNTH) Presents An OpportunityFebruary 23, 2024 | ca.finance.yahoo.comLNTH Apr 2024 110.000 callFebruary 23, 2024 | markets.businessinsider.comAssessing Lantheus Holdings: Insights From 4 Financial AnalystsFebruary 23, 2024 | finance.yahoo.comLantheus Holdings, Inc. (NASDAQ:LNTH) Q4 2023 Earnings Call TranscriptFebruary 23, 2024 | ca.finance.yahoo.comLNTH Mar 2024 30.000 putSee More Headlines Receive LNTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today3/28/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolNASDAQ:LNTH CUSIPN/A CIK1521036 Webwww.lantheus.com Phone(978) 671-8001Fax978-671-8860Employees834Year FoundedN/APrice Target and Rating Average Stock Price Target$104.14 High Stock Price Target$127.00 Low Stock Price Target$82.00 Potential Upside/Downside+72.3%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)$4.64 Trailing P/E Ratio13.03 Forward P/E Ratio10.57 P/E GrowthN/ANet Income$326.66 million Net Margins25.20% Pretax Margin31.70% Return on Equity63.16% Return on Assets27.08% Debt Debt-to-Equity Ratio0.69 Current Ratio5.80 Quick Ratio5.45 Sales & Book Value Annual Sales$1.30 billion Price / Sales3.20 Cash Flow$6.91 per share Price / Cash Flow8.75 Book Value$11.91 per share Price / Book5.08Miscellaneous Outstanding Shares68,550,000Free Float67,523,000Market Cap$4.14 billion OptionableOptionable Beta0.55 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Brian A. Markison (Age 65)CEO & Director Comp: $137.5kMr. Paul M. Blanchfield (Age 43)President Comp: $962.41kMr. Robert J. Marshall Jr. (Age 57)CFA, CFO & Treasurer Comp: $1.06MMr. Daniel M. Niedzwiecki (Age 47)Chief Administrative Officer, General Counsel & Corporate Secretary Comp: $871.93kMr. Etienne Montagut (Age 49)Chief Business Officer Comp: $789.15kMs. Andrea Sabens (Age 45)Chief Accounting Officer Ms. Dorothy BarrSenior Vice President of Manufacturing & Technical OperationsMr. Mark Richard KinarneySenior Director of Investor RelationsMs. Linda S. Lennox (Age 58)VP of Corporate Communications & Chief of Staff Ms. Carol Walker (Age 61)Senior Vice President of Quality More ExecutivesKey CompetitorsNeogenNASDAQ:NEOGQuidelOrthoNASDAQ:QDELRiot PlatformsNASDAQ:RIOTIntellia TherapeuticsNASDAQ:NTLACelldex TherapeuticsNASDAQ:CLDXView All CompetitorsInsiders & InstitutionsNomura Holdings Inc.Bought 407,507 shares on 3/27/2024Ownership: 0.030%PNC Financial Services Group Inc.Bought 1,202 shares on 3/22/2024Ownership: 0.014%Vanguard Group Inc.Sold 15,908 shares on 3/11/2024Ownership: 10.176%Lantheus Alpha Therapy, LlcBought 60,431,039 shares on 3/6/2024Total: $57.41 M ($0.95/share)Fisher Asset Management LLCSold 3,280 shares on 3/5/2024Ownership: 0.231%View All Insider TransactionsView All Institutional Transactions LNTH Stock Analysis - Frequently Asked Questions Should I buy or sell Lantheus stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LNTH shares. View LNTH analyst ratings or view top-rated stocks. What is Lantheus' stock price target for 2024? 7 brokers have issued 12-month target prices for Lantheus' stock. Their LNTH share price targets range from $82.00 to $127.00. On average, they predict the company's share price to reach $104.14 in the next year. This suggests a possible upside of 72.3% from the stock's current price. View analysts price targets for LNTH or view top-rated stocks among Wall Street analysts. How have LNTH shares performed in 2024? Lantheus' stock was trading at $62.00 on January 1st, 2024. Since then, LNTH stock has decreased by 2.5% and is now trading at $60.46. View the best growth stocks for 2024 here. When is Lantheus' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our LNTH earnings forecast. How were Lantheus' earnings last quarter? Lantheus Holdings, Inc. (NASDAQ:LNTH) announced its quarterly earnings data on Thursday, February, 22nd. The medical equipment provider reported $1.59 EPS for the quarter, beating the consensus estimate of $1.33 by $0.26. The medical equipment provider had revenue of $354 million for the quarter, compared to the consensus estimate of $350.44 million. Lantheus had a net margin of 25.20% and a trailing twelve-month return on equity of 63.16%. What ETFs hold Lantheus' stock? ETFs with the largest weight of Lantheus (NASDAQ:LNTH) stock in their portfolio include Harbor Health Care ETF (MEDI), Invesco S&P MidCap Momentum ETF (XMMO), SPDR S&P Health Care Equipment ETF (XHE), Harbor Small Cap Explorer ETF (QWST), American Century Mid Cap Growth Impact (MID), Invesco S&P MidCap 400 Pure Growth ETF (RFG), First Trust Active Factor Small Cap ETF (AFSM) and SoFi Next 500 ETF (SFYX). What guidance has Lantheus issued on next quarter's earnings? Lantheus updated its first quarter 2024 earnings guidance on Thursday, February, 22nd. The company provided earnings per share guidance of 1.500-1.540 for the period, compared to the consensus EPS estimate of 1.510. The company issued revenue guidance of $347.0 million-$355.0 million, compared to the consensus revenue estimate of $336.4 million. What is Mary Anne Heino's approval rating as Lantheus' CEO? 4 employees have rated Lantheus Chief Executive Officer Mary Anne Heino on Glassdoor.com. Mary Anne Heino has an approval rating of 51% among the company's employees. This puts Mary Anne Heino in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Lantheus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lantheus investors own include (MBBYF) (MBBYF), Energy Transfer (ET), Paratek Pharmaceuticals (PRTK), Catalyst Pharmaceuticals (CPRX), Amicus Therapeutics (FOLD), Anavex Life Sciences (AVXL), Exelixis (EXEL), Gerdau (GGB), Pieris Pharmaceuticals (PIRS) and Abeona Therapeutics (ABEO). When did Lantheus IPO? Lantheus (LNTH) raised $75 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 7,900,000 shares at a price of $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager. Who are Lantheus' major shareholders? Lantheus' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (10.18%), Vanguard Group Inc. (10.18%), Price T Rowe Associates Inc. MD (2.39%), Price T Rowe Associates Inc. MD (2.39%), Westfield Capital Management Co. LP (2.28%) and Reinhart Partners LLC. (1.98%). Insiders that own company stock include Andrea Sabens, Brian A Markison, Carol Walker, Daniel Niedzwiecki, Etienne Montagut, Gerard Ber, John J Bolla, Lantheus Alpha Therapy, Llc, Mary Anne Heino, Michael P Duffy, Minnie Baylor-Henry, Paul Blanchfield, Robert J Jr Marshall and Sam R Leno. View institutional ownership trends. How do I buy shares of Lantheus? Shares of LNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LNTH) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap Profits“Cash Frenzy” to Hit Banks on March 20?Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantheus Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.